Almirall, S.A. (BME:ALM)
Spain · Delayed Price · Currency is EUR | Market Cap | 2.30B -4.1% |
| Revenue (ttm) | 1.16B +9.8% |
| Net Income | 59.13M +177.1% |
| EPS | 0.28 +179.0% |
| Shares Out | 217.78M |
| PE Ratio | 38.15 |
| Forward PE | 22.60 |
| Dividend | 0.19 (1.78%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | 146,048 |
| Open | 10.62 |
| Previous Close | 10.54 |
| Day's Range | 10.60 - 10.80 |
| 52-Week Range | 10.02 - 13.98 |
| Beta | 0.17 |
| Analysts | Buy |
| Price Target | 14.30 (+33.9%) |
| Earnings Date | Nov 9, 2026 |
About Almirall
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal sys... [Read more]
Full Company ProfileFinancial Performance
In 2025, Almirall's revenue was 1.11 billion, an increase of 12.51% compared to the previous year's 990.63 million. Earnings were 46.15 million, an increase of 354.85%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ALM stock is "Buy." The 12-month stock price target is €14.30, which is an increase of 33.90% from the latest price.
News
Almirall Earnings Call Transcript: Q2 2026
Net sales rose 7.5% to EUR 603 million in H1 2026, led by strong European dermatology growth and robust performance from Ilumetri and Ebglyss. EBITDA margin reached 25%, achieving the 2028 target early, and full-year guidance is reiterated with further acceleration expected in H2.
Almirall Slides: Q2 2026
Almirall has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 24, 2026.
Almirall Quarterly report: Q2 2026
Almirall has published its Q2 2026 quarterly earnings report on July 24, 2026.
Almirall Earnings Call Transcript: Q1 2026
Q1 2026 saw steady growth driven by strong biologics performance, especially Ebglyss and Ilumetri, with net sales up 2.2% year-over-year and robust expansion in European dermatology. Guidance for 2026 is reiterated, supported by a deep pipeline and disciplined capital allocation.
Almirall Slides: Q1 2026
Almirall has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business
BARCELONA--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its financial results for the first quarter of 2026. Almirall contin...
Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology
BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, have announced an expanded collaboration with the Barcelona Supercomputing...
Almirall presents long-term interim results from Phase 3b ADlong study
Almirall (LBTSF) presents long-term interim results from the ongoing Phase 3b ADlong study evaluating the efficacy and safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic d...
Almirall presents clinical, real-word data across portfolio at AAD meeting
Almirall (LBTSF) is presenting a broad range of clinical and real-world data across its portfolio at the 2026 American Academy of Dermatology Annual Meeting. The company’s presence includes more than…
AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
DENVER--(BUSINESS WIRE)--Almirall S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio at t...
Almirall's 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology
BARCELONA, Spain & PRAGUE--(BUSINESS WIRE)--Almirall, a global biopharmaceutical company dedicated to medical dermatology, this weekend hosted the 17th edition of Skin Academy, a premier scientific me...
Spain's Almirall in talks with 'dozens' of firms to license China assets, CEO says
Almirall is in talks with "dozens" of companies from China to license rights to medicines for other markets, CEO Carlos Gallardo said on Thursday, as the Spanish pharmaceutical company competes with ...
Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships
SHANGHAI & BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology based in Barcelona, today holds an institutional event to inaugu...
Almirall downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Niall Alexander downgraded Almirall (LBTSF) to Hold from Buy with a EUR 14 price target
Almirall profit quadruples in 2025 as dermatology fuels growth push
Almirall, a pharmaceutical firm based in Spain, ended 2025 with a net profit of €46.2 million, which was 357% more than its 2024 profit of €10.1 million. The Barcelona-based pharmaceutical company was...
Almirall Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 12.4% net sales growth and 21% EBITDA increase, driven by European dermatology and biologics. 2026 guidance targets 9%-12% sales growth and continued margin expansion, supported by a robust pipeline and financial flexibility.
Almirall Quarterly report: Q4 2025
Almirall has published its Q4 2025 quarterly earnings report on February 23, 2026.
Almirall Slides: Q4 2025
Almirall has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 23, 2026.
Almirall downgraded to Neutral from Outperform at BNP Paribas
BNP Paribas analyst Francisco Ruiz downgraded Almirall (LBTSF) to Neutral from Outperform with a EUR 14 price target
Almirall Slides: 44th Annual J.P. Morgan Healthcare Conference Presentation
Almirall has posted slides in relation to its latest quarterly earnings report, which was published on January 13, 2026.
Almirall Earnings Call Transcript: Q3 2025
Strong year-to-date growth driven by dermatology portfolio, with Illumetri and Ebgly leading sales increases. Guidance for 2025 is reiterated, targeting double-digit net sales CAGR through 2030 and a 25% EBITDA margin by 2028. Margin pressure from royalties and evolving competition noted.
Almirall Earnings release: Q3 2025
Almirall released its Q3 2025 earnings on November 10, 2025, summarizing the period's financial results.
Almirall Slides: Q3 2025
Almirall has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 10, 2025.
Almirall Earnings Call Transcript: Q2 2025
Strong H1 2025 results with 13% net sales growth, led by ILUMETRI and Eblis, support reaffirmed guidance and midterm outlook. Robust pipeline progress, disciplined capital allocation, and low leverage position the company for continued growth.
Almirall Quarterly report: Q2 2025
Almirall has published its Q2 2025 quarterly earnings report on July 25, 2025.